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The aim of this study was to investigate the involvement of the transient receptor potential ankyrin 1
(TRPA1) in haemorrhagic cystitis, the main side effect of cyclophospha mide-based chem otherapy. Han- 
nover female rats received intraperitoneal (i.p.) injecti on of cyclophospha mide (three doses of 100 mg/ 
kg, every other day, in a total of ﬁve days). This treatment was followed by the treatment with TRPA1 
antag onist HC 030031 (50 mg/kg, p.o.). The threshold for hindpaw withdrawal or abdominal retraction 
to von Frey Hair and the locomotor activity were measured. The treatment with the TRPA1 antagonist 
HC 030031 signiﬁcantly decreased mechanical hyperalgesia induced by cyclophosphamide without inter- 
fere with locomotor activity. Urodynamic parameters were performe d by cystometry 24 h after a single 
treatment with cyclophospha mide (200 mg/kg , i.p.) in control and HC 030031 treated rats. Analyses of 
the urodynamic parameters showed that a single dose of cyclophosphamide was enough to signiﬁcantly
increase the numbe r and amplitude of non-voiding contraction s and to decrease the voided volume and 
voiding efﬁciency, without signiﬁcantly altering basal, threshold or maximum pressure. The treatment 
with HC 030031 either before (100 mg/kg, p.o.) or after (30 mg/kg , i.v.) cyclophosphamide inhibited 
the non-voiding contractions but failed to counteract the loss in voiding efﬁciency. Our data demon- 
strates that nociceptive symptoms and urinary bladder overactivity caused by cyclophosphamide, in part, 
are dependent upon the activation of TRPA1. In this context, the antag onism of the receptor may be an 
alternative to minimise the urotoxic symptoms caused by this chemotherapeutic agent. 
 2013 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction 
Cyclophospham ide is an alkylating agent that has long been 
used in the treatment of solid tumours, lymphom a, myeloma and 
chronic lymphocytic leukaemia. More recently, cyclophospham ide 
has been employed for the treatment of non-neoplastic diseases, 
including thrombocy topenic purpura, rheumatoid arthritis, sys- 
temic lupus erythematosus and as a conditioner before bone mar- 
row transplanta tion [1–3]. Side effects for the treatment with 
cyclophospham ide were described by Coggins and co-workers as 
early as 1960 [4]. Among the side effects, the urologica l distur- 
bances present the major limiting factor in its use. Effects vary from transient irritating voiding symptoms, such as urinary fre- 
quency, dysuria, urgency, suprapubic discomfort and strangury 
with microhae maturia, to life-threaten ing haemorrhagi c cystitis. 
Urinary bladder ﬁbrosis, necrosis, contracture and vesicoureter al 
reﬂux were also associate d with cyclophosphami de therapy [4,5].
The urotoxicity of cyclophosphami de is not directly related to 
its alkylating activity but rather to the formatio n of hydroxylate d
metaboli tes, particularly acrolein, which is formed from hepatic 
microsom al enzymatic hydroxylation for further renal excretion 
[6]. The storage of acrolein within the urinary bladder causes irri- 
tation of the urothelium resulting in inﬂammation that is charac- 
terised by urinary bladder hyperreﬂexia [7]. In addition, acrolein 
is reported to be the most reactive of the a,b-unsaturated alde- 
hydes, and rapidly binds to and depletes cellular nucleophiles such 
as glutathione . Acrolein can also react with some proteins residues 
and nucleophilic sites in DNA. Of note, Bautista and collaborator s
(2006) demonstrat ed that acrolein produced a robust increase in 
calcium inﬂux that was selectively dependent on TRPA1 [8,9].
TRPA1 is a calcium-p ermeable nonselective ion channel with six 
transmemb rane domains and a unique ankyrin repeat in the amino 
terminal portion that contains cysteine residues that are sensitive 
Diagram 1. 
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targets for electrophili c compound s and so the receptor is sensitive 
to a broad range of naturally occurring compounds including: allyl 
isothiocyan ate; cinnamalde hyde; allicin; the environmental irri- 
tant acrolein; the volatile irritant formalin and the end-products 
of bacterial , inﬂammatory and oxidative stress hydrogen sulphide ,
hypochlorid e, hydrogen peroxide, 4-hydronon enal and 4-oxo-non- 
enal [11,12]. TRPA1 is highly expresse d in unmyelinat ed and thinly 
myelinated sensory neurons [10,13,14]. The receptor was identi- 
ﬁed in neuronal and non-neuron al structure s of the lower urinary 
tract, including unmyelinated nerve ﬁbres innervating the epithe- 
lial cells (urothelium), the suburothelial space, muscle layers and 
blood vessels of the rodent urinary bladder [13,15] and in the hu- 
man urethra [16].
The role of TRPA1 in pathological processes of the lower urinary 
tract has been suggested because the receptor is overexpressed in 
urinary bladder mucosa of patients suffering outlet obstruction of 
this organ and in the urothelium and neurons innervati ng the uri- 
nary bladder of rats undergoing spinal cord injury [17,18]. TRPA1 
mediates the contractile response caused by allyl isothiocyan ate 
and cinnamalde hyde in the rat urinary bladder [19] and the intra- 
vesical administrat ion of TRPA1 agonists cause urinary bladder 
overactivity [15,20].
Taking into account the role of TRPA1 in the pathophysiol ogical 
processes of the lower urinary tract and its sensitivity to the cyclo- 
phosphamid e-metabolite acrolein, we hypothesised that antago- 
nism of TRPA1 by a selective antagonist, HC 030031, would 
minimise the urotoxic symptoms caused by cyclophospham ide 
treatment and in turn, decrease the side effects of this chemoth er- 
apeutic drug. Therefore, we evaluated the role of the TRPA1 antag- 
onist HC 030031 in the urodynamic paramete rs and in the 
nociceptive responses in rats that were treated with 
cyclophospham ide. 2. Material and methods 
2.1. Animals 
Female Hannover rats weighing 150–250 g, age 6–7 weeks, 
were used. Animals were housed in cages (up to four per cage) in 
racks model ALERK-dg-50 (Alesco Ind. & Com. Ltda, São Paulo, Bra- 
zil) with ventilated control. The room was maintained at a constant 
temperature of 22 ± 2 C under a 12 h light/12 h dark cycle at 60–
80% humidity with food and water available ad libitum . The rats 
were maintained together as long as they were born to ensure that 
they were under the same estrous cycle during the analyses. In our 
hands, cyclophosphami de presented broader toxicity to male than 
female and this caused a limitation to the experime ntal model in 
males. The experime ntal procedures were approved by the ethics 
committee of the Federal University of Santa Catarina (PP00607)Diagram 2. and followed the National Institutes of Health Animal Care Guide- 
lines (NIH Publicati ons N 80-23).
2.2. Treatmen t protocol 
For behaviou ral assessment, rats (n = 6 per group) received 
three doses of 100 mg/kg cyclophosphami de via intraperi toneal 
(i.p.) on the ﬁrst, third and ﬁfth days (Diagram 1). This schedule 
of treatment allows the installati on of urinary cystitis before start- 
ing any therapeutic treatment and mediates a sub chronic inﬂam-
matory situation . This schedule of treatment was followed as 
described before for female rats [21], with minor modiﬁcations. 
Twenty-fou r hours after the third injection , on the sixth day, rats 
received the ﬁrst treatment with HC 030031 (50 mg/kg) by gavage 
(p.o.). Treatment with HC 030031 was repeated every twelve 
hours, with three doses of HC 030031 in total. The mechanical 
threshold and the locomotor activity were evaluated before the 
treatments (baseline) and after the ﬁrst and third doses of HC 
030031. The rats were not fed during behavioural tests. 
To understand the mechanisms of cyclophosphami de-induced 
urotoxicity, the urodynamic parameters were taken twenty-four 
hours after a single dose of cyclophospham ide (200 mg/kg, i.p.)
[22]. This acute treatment allows investigating earlier mechanisms 
of cyclophospham ide-induced urotoxicity. When investiga ting the 
effects of the TRPA1 receptor antagonist, reproduci ble micturition 
cycles were recorded before (used as baseline values) and during 
45 min following administ ration of HC 030031 (30 mg/kg, 0.1 ml/ 
min for 10 min) or vehicle (8% DMSO + 2% Tween 80 in saline),
intravenousl y (i.v., caudal vein) (Diagram 2A). The administrat ion 
of HC 030031 24 h after cyclopho sphamide intended to evaluate 
the role of TRPA1 receptor after installati on of haemorrhagi c cysti- 
tis. The dose of the antagonist was selected on the basis of previous 
studies and this percentage of DMSO has not altered cystometric 
paramete rs [17]. To evaluate whether the antagonism of TRPA1 
would display some preventive effect against haemorr hagic 
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rats with HC 030031 (100 mg/kg, p.o.) one hour before cyclopho s- 
phamide (Diagram 2B). The groups (n = 6 rats per group) were 
divided in naïve; cyclophosphami de (200 mg/kg, i.p.); HC 030031 
(100 mg/kg, p.o.) one hour before cyclopho sphamide (200 mg/kg, 
i.p.); HC 030031 (30 mg/kg, i.v.) 24 h after cyclopho sphamide 
(200 mg/kg, i.p.).
Both behavioural and urodymic analysis were performed in a
double-blind ed scheme for the treatment and measure ments. 
2.3. Mechanical hyperalge sia 
The mechanical hyperalgesia induced by the i.p. injection of 
cyclophospham ide was evaluated through the application of von 
Frey Hair to the rat hindpaw and abdomin al cavity, according to 
the method previously described [23,24], with some modiﬁcations. 
Rats were individually placed in clear Plexiglas boxes 
(13.8 cm  18.0 cm  68.2 cm) on an elevated wire-mes h platform 
(23.0 cm  39.8 cm  72.7 cm) to allow access to the abdominal 
and plantar surface of both hindpaws. The animals were acclima- 
tised for at least 1 h prior to the behaviou ral test. The withdrawal 
response was quantiﬁed by means of the electronic pressure-mete r
test for rats, which consisted of a hand-held force transducer ﬁtted
with a 0.7 mm 2 polypropylene tip (electronic von Frey anesthesi- 
ometer, IITC Inc., Life Science Instruments , USA). The stimulus 
was applied on the plantar surface of the left hindpaw and on Fig. 1. Mechanical hyperalgesia and locomotor activity in cyclophosphamide (CPP)-indu
of von Frey Hair (VFH) (A) on the abdominal area or (B) on the plantar surface. The rats r
5th. Mechanical hyperalgesia was assessed after the third dose of HC 030031 (50 mg/k
evaluated 6 h after the last treatment with HC 030031. Data are the mean ± S.E.M. of six
the saline-treated group and #P < 0.05 from the cyclophosphamide-treated group (two-the lower abdominal cavity. The intensity of the stimulus (g) was 
automatical ly recorded when the paw was withdraw n or when 
the abdomen was retracted. The stimulus was applied three times 
alternatel y and the mean of these values was registered as the 
mean force supported by the rat. The nociceptive responses were 
evaluated at different time-poi nts following cystitis induction. All 
groups were evaluated before cyclophospham ide injection in order 
to determine the baseline mechanical thresholds. 
2.4. Locomotor activity 
The locomotor performanc e was scored, evaluating the number 
of crossings and rearings by the open-ﬁeld test. For this purpose, 
rats were separated in four groups: vehicle, cyclophosphami de, 
HC 030031, cyclophosphami de plus HC 030031, as described in 
the treatment protocol, and placed in the centre of a round open- 
ﬁeld (50  98  80 cm), in which the ﬂoor was divided into 12 
areas. The number of areas crossed and the rearing responses 
was recorded for 5 min. 
2.5. Cystometri c parameters 
For the urodynamic studies, rats were anaesthe tised with ure- 
thane (1.1 g/kg, i.p.). A PE-60 polyethylene catheter (Clay Adams, 
Parsippa ny, NJ, USA) was inserted via a midline abdominal incision 
into the bladder through its dome. The intravesical catheter was ced haemorrhagic cystitis. Mechanical hyperalgesia was assessed by the application 
eceived three doses of cyclophosphamide (100 mg/kg, i.p.) on the days 1st, 3rd and 
g, p.o.). (C) The crossing and (D) the rearing numbers in the open-ﬁeld test were 
 individuals. The asterisks denote a statistically signiﬁcant difference ⁄P < 0.05 from 
way ANOVA followed by Newman–Keuls Multiple Comparison test).
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(ADInstruments Pty Ltd., Castle Hill, Australia ) and to a micro- 
infusion pump (Insight Equipamentos Cientíﬁcos, Ribeirão Preto, 
SP, Brazil) for recording intravesical pressure and infusing saline 
into the bladder, respectively . Intravesical pressure was continu- 
ously recorded using data acquisition software (PowerLab 8/30, 
ADInstruments ). After catheter implantation, rats were left undis- 
turbed for the next 30 min for bladder stabilisation. After this 
period, saline at 37 C was infused at a rate of 0.1 ml/min. 
We assessed the micturiti on pressure (MP, maximum bladder 
pressure during micturition), basal pressure (BP, the lowest blad- 
der pressure between micturitions), and threshold pressure (TP,
bladder pressure immediately before micturition). The number 
and mean amplitude of non-voiding contraction s (NVCs) were also 
measured. Non-voiding contractions were deﬁned as a rhythmic 
intravesical pressure increase greater than 5 mmHg from baseline 
pressure without release of saline from the urethra. 
The volume of voided saline from urethral meatus was collected 
and measured to determine voided volume [25]. In order to 
measure residual volume, the saline infusion was stopped at the 
beginning of the voiding contraction, and the residual volume 
(RV) was measure d by harvesting saline through the intravesical 
catheter and then manually expressing the remaining intravesical Fig. 2. Urodynamic proﬁle in CPP-induced haemorrhagic cystitis. The number (A) and am
single injection of cyclophosphamide (200 mg/kg, i.p.). The HC 030031 (100 mg/kg) w
intravenous route (i.v., 30 mg/kg, 0.1 ml/min for 10 min) 24 h after cyclophosphamid
administration of HC 030031. Each column represents the mean, and the vertical lines ind
compared with the cyclophosphamide-treated group (one-way ANOVA followed by Ne
during bladder-ﬁlling phase in (C) naïve; (D) 24 h after HC 030031 p.o.; (E) following H
Tween 80 in saline); (G) cyclophosphamide plus HC 030031 (100 mg/kg, p.o.); (H) cyclop
over the cystometograms represent the non-voiding and voiding contractions, respectivcontents by exerting pressure on the bladder abdominal wall. 
The bladder capacity (BC) was calculated as the voided volume 
plus the residual volume, and the voiding efﬁciency (VE) was 
determined as a percentage using the following equation: VE =
[(VV/BC)  100]. The cystomet ric parameters were calculated from 
voiding cycles obtained during 45 min. 2.6. Statistica l analysis 
Results are presented as mean ± S.E.M of six animals. Data were 
analysed by one or two-way analyses of variance (ANOVA)
followed by Newman–Keuls test when appropriate. P values less 
than 0.05 (P < 0.05) were indicative of signiﬁcance. 3. Results 
The systemic treatment with cyclophosphami de caused a persis- 
tent hyperalgesia as evidenced by a decrease in withdraw al 
response threshold to von Frey Hair stimuli [F (4; 16) = 6.929; 
P < 0.002]. There was a similar response when the stimulus was 
applied on the abdominal area or on the hindpaw surface [F (4;
16) = 1.278; P > 0.05] (Fig. 1A). This suggests that cyclopho sphamide plitude (B) of non-voiding contractions (NVCs) were evaluated in rats 24 h after a
as administered by oral gavage (p.o.) one hour before cyclophosphamide or by 
e. In the i.v. treatment the measurements were performed for 45 min following 
icate the S.E.M. of six animals. ⁄P < 0.05 from the saline-treated group and #P < 0.05 
wman–Keuls Multiple Comparison test). The representative traces of cystometry 
C 030031 i.v.; (F) cyclophosphamide plus vehicle for HC 030031 (8% DMSO plus 2% 
hosphamide plus HC 030031 (30 mg/kg, i.v.). The continuous and the dotted arrows 
ely. Each peak that is a voiding contraction represents a micturition. 
Fig. 3. Urodynamic proﬁle in CPP-induced haemorrhagic cystitis. (A) The voided volume and (B) voiding efﬁciency in naive or cyclophosphamide-treated (200 mg/kg, i.p.) rats 
that were under a pre-treatment with vehicle (8% DMSO plus 2% Tween 80) or HC 030031 (100 mg/kg, p.o.) or under a post-treatment with HC 030031 (30 mg/kg i.v.). Each 
column represents the mean, and the vertical lines indicate the S.E.M. of six animals. ⁄P < 0.05 from the saline-treated group (one-way ANOVA followed by Newman–Keuls
Multiple Comparison test).
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perform the next experiments as it offers a more reliable method 
for evaluating withdrawal response. Cyclophospham ide induced a
consistent and reproducibl e hyperalgesia from one to six hours; 
hence we assumed that this scheme of treatment was consistent 
with the progress of urinary bladder cystitis. Once urinary bladder 
cystitis had been installed, the treatment with TRPA1 antagoni st 
HC 030031 (50 mg/kg, p.o.) was started. After the third dose of HC 
030031 (second day of treatment) there was a mild but signiﬁcant
reduction of hyperalgesi a. The anti-hyperal gesic effect was signiﬁ-
cant only one hour after HC 030031 treatment (Fig. 1B).
Rats treated with cyclopho sphamide also presented locomotor 
alterations, which were likely related to the abdomin al discomfort 
caused by cystitis (Fig. 1C and D). As a result, we detected a signif- 
icant decrease in the numbers of crossing [F (1; 24) = 14.314; 
P < 0.05] and rearing [F (1; 24) = 17.588; P < 0.05] in rats that re- 
ceived cyclopho sphamide. The treatment with three doses of HC 
030031 in healthy rats did not alter either crossing [F (1;
24) = 0.026; P > 0.05] or rearing [F (1; 24) = 0.078; P > 0.05] num- 
bers, showing that HC 030031 did not cause any sedative effect 
at this schedule of treatment. In addition, HC 030031 did not sig- 
niﬁcantly attenuate the reduction in locomotor activity caused by 
cyclophospham ide. No signiﬁcant interactions were detected for 
the combined treatment in crossing [F (1; 24) = 0.779; P > 0.05] 
and rearing [F (1; 24) = 0.128; P > 0.05] tests (Fig. 1C and D).
The urotoxic effect of cyclopho sphamide was conﬁrmed
through cystometric analyses. The histogram at the Fig. 2A and B
illustrates the number of the non-voiding contraction s (NVCs)
and the amplitude of these NVCs contractions. The NVCs were 
deﬁned as the rhythmic intravesical pressure greater than 5 mmHg 
from baseline pressure, without the release of saline from the 
urethra. The NVCs are identiﬁed by the continuous arrows over 
the peaks (Fig. 2F and G). Naive rats did not show any NVCs during 
the bladder-ﬁlling phase and each peak at the trace represents a
micturition (Fig. 2C, dotted arrow). Oppositely to the naïve rats, 
the treatment with cyclophospham ide induced a marked number 
of NVCs, with high amplitud e in these contraction s, indicating 
spontaneou s detrusor overactivi ty (Fig. 2F). Treatment with cyclo- 
phosphamid e induced polymorphi c micturition cycles with impro- 
per storage and voiding phase leading to bladder distension. 
Interesting, the systemic pre-treatment with HC 030031 
(100 mg/kg, p.o.) decreased NVCs by 68.75 ± 1.3% (Fig. 2G). Addi- 
tionally, the post-treatmen t with HC 030031 (30 mg/kg, i.v.)
completely abolished the NVCs induced by cyclopho sphamide 
(Fig. 2H). The administrat ion of HC 030031 either by oral or intra- 
venous route did not alter cystomet ric parameters by itself (Fig. 2D
and E).Rats treated with cyclophospham ide also presente d a decrease d
voided volume and voiding efﬁciency, achieving only 32 ± 2.9% and 
13 ± 2.6% activity of the control, respectively (Fig. 3A and B). The 
intravenous administ ration of HC 030031 partially recovered 
voided volume by 45 ± 2.3% and to a better degree the voiding 
efﬁciency, with 57 ± 8.8% activity of the healthy control (Fig. 3B).
The oral treatment with HC 030031 prevented neither voided vol- 
ume nor voiding efﬁciency impairment. The cystometric analysis 
also revealed a slight increase in basal and threshold pressure 
and a slight decrease in maximum pressure; none of these altera- 
tions were signiﬁcant. Both schedule s of HC 030031 treatment 
presente d similar proﬁles to that with the cyclophosphami de trea- 
ted group (Fig. 4).4. Discussion 
The urologica l symptom s caused by cyclophosphami de are well 
characteri sed side effects during chemotherape utic interventions 
[4,5,26,2 7] . In this context, acute or chronic treatments with cyclo- 
phosphami de have been widely used as models for haemorrhagic 
cystitis in rodents, either to identify the intracellular pathways in- 
volved in haemorrhagic cystitis or to search for new drugs to offset 
the pathologi cal state. Chronic administ ration of cyclopho spha- 
mide causes abdominal mechanical hyperalgesia and urinary blad- 
der overactivity in mice, as assessed by von Frey Hair application 
and cystometry [28]. Furthermore, acute and chronic treatment 
with cyclophospham ide causes bladder dysfunction in female rats 
[29]. In this study, we have extended these ﬁndings and demon- 
strated that treatment with cyclophosphami de induces mechanical 
hyperalges ia and overactivity of the urinary bladder in rats. 
In a recent review, Geppetti and collaborators reported that 
cyclopho sphamide induces a neurogen ic inﬂammation in the low- 
er urinary tract, suggesting that its metabolite, acrolein, directly 
activates TRPA1 receptors from sensory neurons. As a consequence, 
the activation of TRPA1 may be due to a secondary inﬂammation
involving c-fos overexpress ion, release of inﬂammatory peptides 
and activation of a1-adrenergi c receptors [30]. Our ﬁndings dem- 
onstrate that the effects of cyclophosphami de/acrolein do not in- 
volve the synthesis of de novo TRPA1 because mRNA expression 
was similar in naive and cyclopho sphamide-trea ted groups (data
not shown). However, these results do not exclude the possibilit y
of post-trans lational changes in the immature form of the protein. 
Acrolein, an important environm ental irritant present in tear 
gas and vehicle exhaust, also targets TRPA1 from pulmonary tissue 
[8]. In vivo , acrolein is formed in conjunction with phosphorami de 
mustard by hydroxylation of cyclophosphami de through hepatic 
Fig. 4. Urodynamic proﬁle in CPP-induced haemorrhagic cystitis. (A) Basal, (B)
threshold, and (C) maximum pressure in naive and cyclophosphamide-treated 
(200 mg/kg, i.p.) rats. The rats received a single dose of vehicle or HC 030031 
(100 mg/kg, p.o.) one hour before cyclophosphamide or HC 030031 (30 mg/kg, i.v.)
24 h after cyclophosphamide. Each column represents the mean, and the vertical 
lines indicate the S.E.M. of six animals. Statistical were performed by one-way 
ANOVA followed by Newman–Keuls Multiple Comparison test. 
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idly enter the uroepithelium because of its chemical nature, where 
it causes its main toxic effect. In agreement with this, the direct 
intravesical injection of acrolein increased vascular bladder perme- 
ability and plasma exudatio n [32].
The direct activation of TRPA1 by acrolein has been demon- 
strated in vitro [8] and this may be the main mechanism by which 
acrolein induces urotoxicity. However, taking into account the low 
concentratio n of acrolein in urine of patients undergoing cyclo- 
phosphamid e treatment, it may also cause urotoxicity by other 
mechanism s [33]. As reported by Korkmaz and collaborators, a
disruption in the redox status of the cell, driven by cyclophospha- 
mide/acrolei n, could be the main inducer of urotoxicity [5]. This 
fact is interesting because the cysteine residues containe d in the 
ankyrin sequence of TRPA1 are, in fact, sensors for the impairment 
of oxidation- reduction status of the cell. Therefore, TRPA1 may be a
direct target for acrolein and also an indirect target for the oxidised 
substances generate d by acrolein accumulation. Of note, the disruption of redox status in the cell may affect other proteins 
and this nonspeciﬁc effect might also contribute to acrolein toxic- 
ity [34].
In the present study, we show an involvement of TRPA1 in the 
urotoxic symptoms of cyclophospham ide treatment. The visceral 
inﬂammation and pain induced by cyclopho sphamide sensitizes 
a somatic area at the spinal cord which causes referred pain 
[24,35,36 ]. In accordance with this, rats treated with cyclophos- 
phamide presented a similar sensitivity when the stimulus (von
Frey Hair) was applied to either the abdominal area or to the 
ventral surface of the hindpaw .
The consecutive treatment with the TRPA1 antagonist HC 
030031 partially decreased mechanical hyperalgesi a suggesting 
that TRPA1 is a putative target to countera ct symptoms related 
to urinary bladder cystitis. The neuronal inputs caused by the 
agonism of TRPA1 in pelvic nerves is an important mechanism to 
cause visceral pain and, therefore, the antagonism of TRPA1 has 
been suggested as a promisor therapy against somatic pain 
[37,38]. TRPA1 activation is associate d with nerve growth fact 
(NGF) synthesis and phospho rylation of p38 [14], a mechanis m
that will maintain hyperalgesi a even in the absence of the initial 
stimulus . Of interest, NGF was overexpressed within bladder and 
in L6/S1 dorsal root ganglia in acute and subacute cystitis induced 
by instillation of acrolein and the systemic treatment with NGF- 
neutraliz ing antiserum or intravesical treatment with a trkA antag- 
onist supressed mechanical hyperalgesia [35]. In fact, NGF has 
been described to contribute to urinary bladder hyperreﬂexia 
[39–42] and somatic sensitivity [43–45].
In addition, the treatment with cyclophosphami de induced an 
overexpress ion of interleukins : IL-1 b, IL-4, IL-18 and interfero n c
[46]. This might contribute to a diffuse inﬂammatory response 
and activation of intracellular messengers. In fact, the treatment 
with cyclophospham ide induced urinary bladder hyperreﬂexia re- 
lated to the activation of JAK-STAT pathway [21], phosphoryla tion 
of Akt [29] and extracellul ar signal regulated kinase (ERK) [47,48].
As a consequence of this inﬂammatory signaling, the synthesis of 
kinins, mast-der ived trypsin, fatty acids metaboli tes, chemoki nes, 
nitric oxide and nitrate derivative compounds will further sensitize 
TRPA1 [49–55].
The urodynami c parameters have conﬁrmed the capability of 
cyclopho sphamide to induce bladder overactivi ty. Overactiv e uri- 
nary bladder is a syndrome characterized by exacerbated contrac- 
tions of the urinary bladder during the ﬁlling phase, associate with 
detrusor sphincter dyssynergi a and inefﬁcient voiding [56,57]. We 
found that a single acute treatment with cyclophospham ide signif- 
icantly increased the number and amplitud e of non-void ing 
contraction s, decreased voided volume and voiding efﬁciency,
but only slightly increased basal and threshold pressure. It is note- 
worthy that voiding efﬁciency is the ratio between the voided 
volume and the urinary bladder capacity, whereas the capacity is 
the total voided volume plus residual volume; therefore, a high 
number of non-voiding contractions in conjunction with a low 
voiding efﬁciency support an overactivity of the organ that is not 
associate d with micturiti on. This is a feature of the bladder 
dysfunct ion during cystitis. Of relevance, these urodynamic param- 
eters are in agreement with previous ﬁndings that used acute 
treatment with cyclophosphami de to induce cystitis [21,58].
The non-voiding contractions are represented by increased 
spontaneou s activity of the detrusor smooth muscle cells during 
the ﬁlling phase, which may cause bladder overactivity. It has been 
shown that the spontaneou s phasic activity of the detrusor tissue is 
myogeni c in origin [59] and that the urotheliu m plays a signiﬁcant
role in modulating the nature of these contractions [60]. Addition- 
ally, the modulation of ion channels in sensory ﬁbers and urothelial 
cells by mechanical stimuli and inﬂammatory cytokine s can lead to 
voiding disorders [61]. Recently , TRPA1 receptor expression has 
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urothelial cells, where it is suggested to act as mechano sensor and 
nociceptor in either physiological or pathologi cal states [15,20]. In 
agreement to these ﬁndings, our study demonst rated that the 
TRPA1 antagonism either before or after urinary bladder cystitis 
developmen t efﬁciently decreased the number and the amplitude 
of non-voiding contraction s. This suggests that urothelium actively 
contributes to bladder contractil e response mediated by TRPA1. 
Previous studies have reported the role of TRPA1 in bladder 
overactivity ; for instance, the TRPA1 agonists allyl isothiocyan ate, 
sodium sulphide or cinnamaldehyde increase the micturition 
frequency, and decrease voiding volume and intercontration inter- 
val [15,20,62]. In addition, both the antagonism by HC 030031 and 
the down-regul ation by anti-sense oligonucleotid e of TRPA1 signif- 
icantly reduced the number and amplitude of non-voiding contrac- 
tions in bladder overactivity induced by spinal cord injury [17].
It is noteworthy to mention that the dysfunction of the external 
urethal sphincter triggers the developmen t of detrusor-sphi ncter 
dyssynergia. In our study, we observed marked alterations in void- 
ing caused by the external urethral sphincter dysfunction such as 
reduced voided volume and voiding efﬁciency and greater urinary 
bladder capacity. These events were only partially recovered by 
TRPA1 antagoni sm. The lack of effectiveness of HC 030031 could 
be explained by a restriction in TRPA1 function, i.e., the receptor 
does not seem to exert any descending control of spinal motor neu- 
rons that regulate external urethral sphincter. However , TRPA1 has 
a signiﬁcant role in to regulate the activity of the urothelium. 
5. Conclusion 
In summary, our ﬁndings demonst rate that treatment with 
cyclophospham ide induces haemorr hagic cystitis with evident 
abdominal discomfort. The urinary bladder overactivi ty and the 
reduction in the nociceptive threshold were depende nt on the 
activation of TRPA1. As mentioned previously, the cyclopho spha- 
mide metabolite, acrolein might be the main agent responsible 
for TRPA1-dependen t urinary bladder dysfunction. Therefore, 
antagonism of TRPA1 may be a strategy to countera ct the urotoxic 
side effects of some chemothera peutic drugs. 
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